Skip to main content

MoneyWorks4Me

Balaxi Pharma. - Quaterly Results

03 Aug 2023 Evaluate
The sales for the June 2023 quarter moved down to Rs. 250.40 millions as compared to Rs. 264.54 millions during the year-ago period.The Company to register a -52.14%  fall in the net profit for the quarter ended June 2023.Operating profit for the quarter ended June 2023 decreased to 38.97 millions as compared to 68.09 millions of corresponding quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 250.40 264.54 -5.35 250.40 264.54 -5.35 1081.38 1012.92 6.76
Other Income 1.26 25.72 -95.10 1.26 25.72 -95.10 66.04 27.48 140.32
PBIDT 38.97 68.09 -42.77 38.97 68.09 -42.77 234.26 200.10 17.07
Interest 2.58 1.96 31.63 2.58 1.96 31.63 4.59 0.61 652.46
PBDT 36.39 66.13 -44.97 36.39 66.13 -44.97 229.67 199.49 15.13
Depreciation 1.31 0.80 63.75 1.31 0.80 63.75 5.15 2.50 106.00
PBT 35.08 65.33 -46.30 35.08 65.33 -46.30 224.52 196.99 13.98
TAX 9.54 11.97 -20.30 9.54 11.97 -20.30 62.29 50.32 23.79
Deferred Tax -0.03 -0.04 -25.00 -0.03 -0.04 -25.00 10.62 0.32 3218.75
PAT 25.54 53.36 -52.14 25.54 53.36 -52.14 162.23 146.67 10.61
Equity 102.30 100.00 2.30 102.30 100.00 2.30 101.81 100.00 1.81
PBIDTM(%) 15.56 25.74 -39.53 15.56 25.74 -39.53 21.66 19.75 9.66
Peers
Company Name CMP
Redington 349.60
Adani Enterprises 2682.00
Amrapali Industries 32.78
Maxgrow India 174.80
Rashi Peripheral 689.15
View more..